Which Market Offer More Value? – Celldex Therapeutics, Inc. (CLDX), Sunesis Pharmaceuticals, Inc. (SNSS)

The shares of Celldex Therapeutics, Inc. have decreased by more than -78.83% this year alone. The shares recently went down by -7.52% or -$0.05 and now trades at $0.60. The shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), has slumped by -39.02% year to date as of 06/13/2018. The shares currently trade at $2.25 and have been able to report a change of -20.49% over the past one week.

The stock of Celldex Therapeutics, Inc. and Sunesis Pharmaceuticals, Inc. were two of the most active stocks on Wednesday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of CLDX is -49.20% while that of SNSS is -447.00%. These figures suggest that CLDX ventures generate a higher ROI than that of SNSS.

Cash Flow

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, CLDX’s free cash flow per share is a negative -0.23, while that of SNSS is also a negative -0.97.

Liquidity and Financial Risk

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for CLDX is 5.50 and that of SNSS is 2.30. This implies that it is easier for CLDX to cover its immediate obligations over the next 12 months than SNSS.


CLDX currently trades at a P/B of 0.63, and a P/S of 5.70 while SNSS trades at a P/S of 446.74. This means that looking at the earnings, book values and sales basis, CLDX is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of CLDX is currently at a -85.47% to its one-year price target of 4.13. Looking at its rival pricing, SNSS is at a -64.45% relative to its price target of 6.33.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), CLDX is given a 2.50 while 2.00 placed for SNSS. This means that analysts are more bullish on the outlook for CLDX stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for CLDX is 2.31 while that of SNSS is just 2.72. This means that analysts are more bullish on the forecast for CLDX stock.


The stock of Sunesis Pharmaceuticals, Inc. defeats that of Celldex Therapeutics, Inc. when the two are compared, with SNSS taking 5 out of the total factors that were been considered. SNSS happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, SNSS is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for SNSS is better on when it is viewed on short interest.

Previous ArticleNext Article

Related Post

Novavax, Inc. (NVAX) vs. Marvell Technology Group ... Novavax, Inc. (NASDAQ:NVAX) shares are up more than 75.00% this year and recently decreased -3.56% or -$0.08 to settle at $2.17. Marvell Technology Gr...
A Comparison of Top Movers: Citigroup Inc. (C), To... The shares of Citigroup Inc. have decreased by more than -8.01% this year alone. The shares recently went up by 0.32% or $0.22 and now trades at $68.4...
Which is more compelling pick right now? – B... The shares of Belden Inc. have decreased by more than -27.62% this year alone. The shares recently went up by 2.48% or $1.35 and now trades at $55.85....
Which Market Offer More Value? – Nabors Indu... The shares of Nabors Industries Ltd. have decreased by more than -5.86% this year alone. The shares recently went up by 1.90% or $0.12 and now trades ...
Set Sail With Alphabet Inc. (GOOG), Ultra Clean Ho... The shares of Alphabet Inc. have increased by more than 0.17% this year alone. The shares recently went up by 2.39% or $24.49 and now trades at $1048....